DDS: development issues and regulatory science.
نویسندگان
چکیده
منابع مشابه
Human cytomegalovirus and transplantation: drug development and regulatory issues
Cytomegalovirus (CMV) infection is highly prevalent worldwide and can cause serious disease among immunocompromised individuals, including persons with HIV and transplant recipients on immunosuppressive therapies. It can also result in congenital cytomegalovirus when women are infected during pregnancy. Treatment and prevention of CMV in solid organ and haematopoietic stem cell transplant recip...
متن کاملRegulatory affairs issues and legal ontologies in drug development.
It usually can take more than ten years from the time a new drug is discovered, until can be launched on the market. Regulatory requirements are part of the process of drug discovery and drug development. It acts at every developmental stage. Regulatory affairs works to establish an effective and uniform balance between voluntary and regulatory compliance and agency responsiveness to consumer n...
متن کاملDevelopment of Antibody–Drug Conjugates Using DDS and Molecular Imaging
Antibody-drug conjugate (ADC), as a next generation of antibody therapeutics, is a combination of an antibody and a drug connected via a specialized linker. ADC has four action steps: systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells, such as through drug delivery system (DDS) drugs. An antibody with a size of ab...
متن کاملPresenting a Model for Student Development Issues
Abstract: This study aimed to provide a multilevel model of student development issues with a qualitative approach, using a systematic review of previous studies and the seven-step meta-combination method of Sandlowski and Barso (2007). For this purpose, to determine the direction of the study, the research question was selected, and then to collect information to answer the research question, ...
متن کاملRegulatory issues in Europe
The EU food labelling regulation tells the food producer that all ingredients in a pre-packaged product need to be in the list of ingredients. There are some exceptions from this general rule, but theses exceptions can not be used if the ingredient is a recognised allergenic food on the EU list. It is also important to note that the producer is obliged to use an easily recognisable name. As an ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drug Delivery System
سال: 2014
ISSN: 0913-5006,1881-2732
DOI: 10.2745/dds.29.226